Wednesday, 18 Sep 2019

You are here

Opioid Use Ups the Risk of Hospitalized Infections in Rheumatoid Arthritis

Researchers from Vanderbilt University have studied the issue of opioid use in rheumatoid arthritis (RA) and whether this influences infection risk.  Based on animal data, researchers have postulated that opioids may further immunosuppress those treated. (Citation source http://buff.ly/1QSPiGJ)

Self-controlled case series analysis of 13,796 RA patients enrolled in Tennessee Medicaid between 1995-2009 looked at the risk of hospitalizations for serious infections during periods of opioid use compared with non-use. These serious infections included pneumonia, meningitis, encephalitis, septicemia and other serious infections.

They found 1,790 RA patients with at least one hospitalization for serious infection, and the adjusted incidence rate of serious infection was higher during periods of current opioid use [incidence rate ratio (IRR: 1.39; 95% CI: 1.19-1.62). The incidence rate was also higher during periods of long-acting opioid use, immunosuppressive opioid use and new opioid use compared with non-use. (These results were adjusted for confounders - age, DMARDs, glucocorticoids, and proton-pump inhibitors.)

RA patients on opioids may have a 40% increased risk of serious infections leading hospitalizations. Whether these are direct or indirect effects was not addressed in these analyses.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. 

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.